Brief: Cosmo Pharmaceuticals FY Net Loss Widens To EUR 24.5 Mln

Cosmo NV

03/04/2020 06:17

April 3 (Reuters) - Cosmo Pharmaceuticals NV  COPN.S :
    * FY LOSS AFTER TAX OF EUR 24.5 MILLION VERSUS LOSS EUR 18.1 MILLION YEAR AGO
    * FY REVENUE EUR 62.5 MILLION VERSUS TO EUR 65.6 MILLION YEAR AGO
    * FY OPERATING LOSS OF EUR12.3 MILLION COMPARED WITH AN OPERATING LOSS OF EUR16.6 MILLION IN
2018
    * FY CASH AND LIQUID INVESTMENTS EUR 268.2 MILLION VERSUS EUR 375.8 MILLION YEAR AGO
    * WILL BE BACK TO OPERATING PROFIT IN 2020
    * SEES CORONAVIRUS PANDEMIC WILL SIGNIFICANTLY SLOW DOWN OR STOP CLINICAL DEVELOPMENT AND/OR
FDA
ACTIVITY
    * OUTLOOK 2020: FULL YEAR REVENUES IN RANGE OF EUR 52 - EUR 56 MILLION
    * OUTLOOK 2020: TOTAL EXPENSES IN RANGE OF EUR 48 - EUR 50 MILLION
    * OUTLOOK 2020: OPERATING PROFIT IN RANGE OF EUR 2 - EUR 8 MILLION

Source text for Eikon:  ID:nTEN67xwya 
Further company coverage:  COPN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))